Athira Pharma Inc
ATHA6.970USD
+0.250+3.72%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
27.49MMarket Cap
LossP/E TTM
More Details of Athira Pharma Inc Company
Athira Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing small molecules to restore neuronal health and slow neurodegeneration. Its approach is designed to modulate the neurotrophic hepatocyte growth factor (HGF) system, which is critical to normal brain function. The Company’s lead drug candidate is ATH-1105. ATH-1105 is a novel, orally available, brain-penetrant small-molecule drug candidate designed to positively modulate the neurotrophic HGF system for the potential treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), and Parkinson’s disease (PD). ATH-1105 is in development for the potential treatment of ALS. Its ATH-1020 is a novel, orally available small molecule drug candidate designed to positively modulate the neurotrophic HGF system. It has evaluated several other compounds in preclinical discovery and development for neurodegenerative diseases and other indications.
Athira Pharma Inc Info
Ticker SymbolATHA
Company nameAthira Pharma Inc
IPO dateSep 18, 2020
CEOLitton (Mark James)
Number of employees26
Security typeOrdinary Share
Fiscal year-endSep 18
Address18706 North Creek Parkway, Suite 104
CityBOTHELL
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code98011
Phone14256208501
Websitehttps://www.athira.com/
Ticker SymbolATHA
IPO dateSep 18, 2020
CEOLitton (Mark James)
Company Executives of Athira Pharma Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Mark James Litton, Ph.D.
Dr. Mark James Litton, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
34.55K
-6.78%
Dr. Kevin Church, Ph.D.
Dr. Kevin Church, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
16.89K
-4.81%
Mr. Mark Worthington
Mr. Mark Worthington
Chief Compliance Officer, General Counsel, Company Secretary
Chief Compliance Officer, General Counsel, Company Secretary
11.19K
-7.08%
Mr. Robert Renninger
Mr. Robert Renninger
Senior Vice President - Finance, Accounting
Senior Vice President - Finance, Accounting
10.92K
-2.59%
Ms. Kelly A. Romano
Ms. Kelly A. Romano
Independent Chairwoman of the Board
Independent Chairwoman of the Board
8.07K
-23.06%
Dr. Javier San Martin, M.D.
Dr. Javier San Martin, M.D.
Chief Medical Officer
Chief Medical Officer
7.17K
-13.14%
Mr. Grant E. Pickering
Mr. Grant E. Pickering
Independent Director
Independent Director
2.58K
--
James A. Johnson ,
James A. Johnson ,
Independent Director
Independent Director
500.00
--
Ms. Barbara Kosacz, J.D.
Ms. Barbara Kosacz, J.D.
Independent Director
Independent Director
--
--
Ms. Julie Rathbun
Ms. Julie Rathbun
Investor Relations
Investor Relations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Mark James Litton, Ph.D.
Dr. Mark James Litton, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
34.55K
-6.78%
Dr. Kevin Church, Ph.D.
Dr. Kevin Church, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
16.89K
-4.81%
Mr. Mark Worthington
Mr. Mark Worthington
Chief Compliance Officer, General Counsel, Company Secretary
Chief Compliance Officer, General Counsel, Company Secretary
11.19K
-7.08%
Mr. Robert Renninger
Mr. Robert Renninger
Senior Vice President - Finance, Accounting
Senior Vice President - Finance, Accounting
10.92K
-2.59%
Ms. Kelly A. Romano
Ms. Kelly A. Romano
Independent Chairwoman of the Board
Independent Chairwoman of the Board
8.07K
-23.06%
Dr. Javier San Martin, M.D.
Dr. Javier San Martin, M.D.
Chief Medical Officer
Chief Medical Officer
7.17K
-13.14%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Dec 20
Updated: Sat, Dec 20
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Perceptive Advisors LLC
13.70%
Simplify Asset Management Inc
7.57%
Baselake Management, LLC
5.63%
Nemean Asset Management, LLC
4.09%
The Vanguard Group, Inc.
3.90%
Other
65.11%
Shareholders
Shareholders
Proportion
Perceptive Advisors LLC
13.70%
Simplify Asset Management Inc
7.57%
Baselake Management, LLC
5.63%
Nemean Asset Management, LLC
4.09%
The Vanguard Group, Inc.
3.90%
Other
65.11%
Shareholder Types
Shareholders
Proportion
Private Equity
13.96%
Investment Advisor
13.62%
Corporation
9.73%
Hedge Fund
4.09%
Venture Capital
3.79%
Individual Investor
3.63%
Investment Advisor/Hedge Fund
2.20%
Family Office
0.98%
Research Firm
0.83%
Other
47.17%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
111
1.69M
59.67%
+2.61K
2025Q3
123
1.85M
67.42%
-29.98K
2025Q2
137
1.88M
68.23%
-792.00
2025Q1
169
1.88M
71.62%
-912.05K
2024Q4
181
1.93M
77.37%
-30.53K
2024Q3
198
1.93M
80.55%
-610.31K
2024Q2
215
2.54M
81.59%
+49.57K
2024Q1
233
2.49M
97.31%
-1.23M
2023Q4
240
2.51M
94.17%
+48.15K
2023Q3
248
2.46M
95.12%
-62.03K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Perceptive Advisors LLC
540.30K
13.7%
--
--
Jun 30, 2025
Simplify Asset Management Inc
149.28K
3.79%
--
--
Jun 30, 2025
Nemean Asset Management, LLC
199.47K
5.06%
+199.47K
--
Apr 14, 2025
The Vanguard Group, Inc.
153.79K
3.9%
--
--
Jun 30, 2025
Tang Capital Management, LLC
60.00K
1.52%
--
--
Jun 30, 2025
Renaissance Technologies LLC
24.10K
0.61%
+2.20K
+10.05%
Jun 30, 2025
Acadian Asset Management LLC
40.55K
1.03%
-2.31K
-5.38%
Jun 30, 2025
Pathstone
37.22K
0.94%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
37.24K
0.94%
-7.40K
-16.58%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Simplify Propel Opportunities ETF
0.92%
iShares Neuroscience and Healthcare ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares US Small-Cap Equity Factor ETF
0%
iShares Micro-Cap ETF
0%
Dimensional US Core Equity 1 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Simplify Propel Opportunities ETF
Proportion0.92%
iShares Neuroscience and Healthcare ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
iShares US Small-Cap Equity Factor ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Sep 11, 2025
Merger
10→1
Date
Type
Ratio
Sep 11, 2025
Merger
10→1
FAQs
Who are the top five shareholders of Athira Pharma Inc?
The top five shareholders of Athira Pharma Inc are:
Perceptive Advisors LLC holds 540.30K shares, accounting for 13.70% of the total shares.
Simplify Asset Management Inc holds 149.28K shares, accounting for 3.79% of the total shares.
Nemean Asset Management, LLC holds 199.47K shares, accounting for 5.06% of the total shares.
The Vanguard Group, Inc. holds 153.79K shares, accounting for 3.90% of the total shares.
Tang Capital Management, LLC holds 60.00K shares, accounting for 1.52% of the total shares.
Perceptive Advisors LLC holds 540.30K shares, accounting for 13.70% of the total shares.
Simplify Asset Management Inc holds 149.28K shares, accounting for 3.79% of the total shares.
Nemean Asset Management, LLC holds 199.47K shares, accounting for 5.06% of the total shares.
The Vanguard Group, Inc. holds 153.79K shares, accounting for 3.90% of the total shares.
Tang Capital Management, LLC holds 60.00K shares, accounting for 1.52% of the total shares.
What are the top three shareholder types of Athira Pharma Inc?
The top three shareholder types of Athira Pharma Inc are:
Perceptive Advisors LLC
Simplify Asset Management Inc
Baselake Management, LLC
Perceptive Advisors LLC
Simplify Asset Management Inc
Baselake Management, LLC
How many institutions hold shares of Athira Pharma Inc (ATHA)?
As of 2025Q4, 111 institutions hold shares of Athira Pharma Inc, with a combined market value of approximately 1.69M, accounting for 59.67% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -7.75%.
What is the biggest source of revenue for Athira Pharma Inc?
In --, the -- business generated the highest revenue for Athira Pharma Inc, amounting to -- and accounting for --% of total revenue.
